RecruitingPhase 2NCT06273072

Metformin IN Asthma for Overweight and Obese Individuals (MINA)

Sponsor

Johns Hopkins University

Enrollment

100 participants

Start Date

Dec 9, 2024

Study Type

INTERVENTIONAL

Conditions

Asthma Overweight and Obesity Asthma Chronic

Summary

This is a randomized clinical trial of metformin among overweight or obese adults with not well-controlled asthma despite maintenance inhaler therapy.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Physician-diagnosed asthma on maintenance therapy
Not well-controlled asthma (ACT score \<20, or at least one asthma exacerbation requiring corticosteroids in the prior 12 months)
Overweight or obesity: Body mass index ≥25kg/m2
Adult: Age ≥18

Exclusion Criteria11

Currently pregnant, expect to become pregnant in the next 6 months or are currently breastfeeding
Major cardiovascular disease: heart failure, heart attack or stroke within the last 6 months
Other chronic lung disease, inclusive of chronic obstructive pulmonary disease, bronchiectasis, interstitial lung disease, pulmonary fibrosis
Active smoking or former smoker with ≥20 pack-year smoking history
Chronic kidney disease: estimated glomerular filtration rate ≤60 mL/min/1.73 m2
Heavy alcohol use: in a typical week, 8 or more drinks for a woman or 15 or more drinks for a man
Liver disease: elevation in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2x the upper limit of normal or prior diagnosis of liver disease
Anemia: hemoglobin \< 13 g/dl in males and hemoglobin \< 11 g/dl in females
Taking Glucagon Like Peptide 1(GLP-1) medications for weight loss
Diabetes (Hemoglobin A1C ≥ 6.5% or taking metformin or other medications used to treat diabetes)
Participation in any other clinical trial (observational studies are permitted)